ASEP Medical Holdings Inc.：高管交易动态
ASEP Medical Holdings Inc.是一家医疗保健行业的上市公司。其高管通过SEDI申报股份交易。过去一年（2025年10月24日至2026年10月24日），共有15份申报出自4位高管。
其中没有任何公开市场买卖，只有股份授予、与激励计划相关的交易和其他操作。这类操作大多属于薪酬安排，作为信号的分量弱于公开市场交易。
作为参照，同一交易所的中位公司（共2,734家公司）同期发布了14份申报，而本公司为15份申报。回溯至覆盖起点2022年，高管共申报4笔买入和6笔卖出。
过去一年，ASEP Medical Holdings Inc.的高管买入记录为空。
如需在同一行业内比较，可查看Dynavox Group AB和EssilorLuxottica的高管买入记录。本摘要仅基于SEDI的披露信息，不预示股价未来走向。
该评分只在所属市场内对买入进行排名。仅在经过回测的策略范围内的交易所提供建议仓位；其他市场的信号仍处于观察状态。并非投资建议。
透明的价值 + 质量排名，独立于内部人交易信号。
财务数据
财年 2025财年截至 2025年12月 · cache
- 180,000 股期权TSXSEDI:4793336
- 2,088,000 股股票TSXSEDI:4793335
- 270,000 股期权TSXSEDI:4793333
- 759,359 股股票TSXSEDI:4793332
- 18,000 股期权TSXSEDI:4793330
- 180,000 股期权TSXSEDI:4793329
- 544,500 股股票TSXSEDI:4793252
- 360,000 股@ CA$0.10100.0% 占其流量股票TSXSEDI:4783984
- 360,000 股@ CA$0.10100.0% 占其流量股票TSXSEDI:4783965
- 787,500 股@ CA$0.10100.0% 占其流量股票TSXSEDI:4783934
- 113,000 股股票TSXSEDI:4783737
- 股票TSXSEDI:4783732
- 1,451,818 股@ CA$0.2467.0% 占其流量股票TSXSEDI:4710342
- 882,041 股@ CA$0.2457.6% 占其流量股票TSXSEDI:4710336
- 413,515 股@ CA$0.2449.9% 占其流量股票TSXSEDI:4710349
- 125,000 股@ CA$0.215100.0% 占其流量股票TSXSEDI:4278939
- 250,000 股@ CA$0.215100.0% 占其流量股票TSXSEDI:4279012
- 125,000 股@ CA$0.21522.4% 占其流量股票TSXSEDI:4278947
- 125,000 股@ CA$0.215100.0% 占其流量股票TSXSEDI:4278930
- 175,000 股@ CA$0.215100.0% 占其流量股票TSXSEDI:4278921
- 100,000 股@ CA$0.21534.3% 占其流量股票TSXSEDI:4278956
- 100,000 股@ CA$0.21539.5% 占其流量股票TSXSEDI:4278967
- 105,000 股@ CA$0.2022.7% 占其流量股票TSXSEDI:4232160
- 15,000 股@ CA$0.323.5% 占其流量股票TSXSEDI:4214950
- 33,500 股@ CA$0.307.3% 占其流量股票TSXSEDI:4214951
44 条申报中的 25 条
About ASEP Medical Holdings Inc.
Derrold Norgaard, a director of ASEP Medical Holdings Inc., signs 9 of the 30 filings in the record, of which 4 purchases, and the three largest: EUR 30,703 on April 12, 2022, EUR 3,332 on February 24, 2022 and EUR 1,116 on February 25, 2022. In all, 4 purchases are worth EUR 36,257, with a median of EUR 2,224. The only two sales, EUR 7,841 on June 21, 2023 and EUR 1,758 on July 18, 2023, come from Murphy Enterprises Inc., filed as a director and senior officer, which has 4 filings in total.
Jacqueline Mae Tucker, a senior officer, signs 6 filings, with no purchase or sale, Richard Heinzl, a director, 4, and Paul Kania, a director, 2. The record also holds 5 grants, 11 option exercises and 8 filings of another kind. Purchases are 67% of market trades by count.
展开全文收起
Filings, published from February 24, 2022 to October 20, 2026, split into 4 for 2022, 7 for 2023, 7 for 2024 and 12 for 2026, the latter making up the last twelve months, with no purchase or sale. The Toronto company, classified under health care, is valued at CAD 3.2 million. The median publication delay is 2 days.
同行业近期入选信号
我们的模型当前为推荐列表排序的买入。
全部推荐
